Recordati in-licences novel neurotrophic keratitis candidate

In the third licensing deal for the company this year, Italian drugmaker Recordati (RECI: MI) has entered a deal to acquire global rights to a low molecular weight peptidomimetic of human nerve growth factor (NGF) for the treatment of neurotrophic keratitis, which already received an orphan drug designation in the European Union, from Rome-based MimeTech.

Additional indications linked to NGF defects are also contemplated in the scope of the partnership. Under the terms of the agreement Recordati will make an undisclosed upfront payment upon signature of the contract and further milestone payments shall be linked to the development process and commercial performance.

Neurotrophic keratitis is a rare degenerative corneal disease which in its more severe forms affects less than one person out of 10,000 worldwide, and is initiated by an impairment of trigeminal nerve. Impairment or loss of corneal sensory innervation is responsible for corneal epithelial defects, ulcer, and perforation. The most common causes of loss of corneal innervation are: viral infection (herpes simplex and herpes zoster keratoconjunctivitis), chemical burns, physical injuries, and corneal surgery.